Erschienen in:
08.12.2015 | Focussed Research Review
Improving cancer immunotherapy with DNA methyltransferase inhibitors
verfasst von:
Mohammad H. Saleh, Lei Wang, Michael S. Goldberg
Erschienen in:
Cancer Immunology, Immunotherapy
|
Ausgabe 7/2016
Einloggen, um Zugang zu erhalten
Abstract
Immunotherapy confers durable clinical benefit to melanoma, lung, and kidney cancer patients. Challengingly, most other solid tumors, including ovarian carcinoma, are not particularly responsive to immunotherapy, so combination with a complementary therapy may be beneficial. Recent findings suggest that epigenetic modifying drugs can prime antitumor immunity by increasing expression of tumor-associated antigens, chemokines, and activating ligands by cancer cells as well as cytokines by immune cells. This review, drawing from both preclinical and clinical data, describes some of the mechanisms of action that enable DNA methyltransferase inhibitors to facilitate the establishment of antitumor immunity.